VivoSeq
Oncology

Relapsed or Refractory Multiple Myeloma (RRMM)

8

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Relapsed or Refractory Multiple Myeloma (RRMM) is an early-stage landscape with 8 programs across 5 companies. The most active players are Excyte Biopharma Ltd, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Sanofi. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Excyte Biopharma Ltd

1 program

Phase 2J

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Multicenter, Open-Label, Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Not yet recruiting·EExcyte Biopharma Ltd·Phase 2·NCT07695740·64 enrolled
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06615479·440 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)